DGAP-News: EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES
03.01.2018 (www.4investors.de) -
DGAP-News: Evotec AG / Key word(s): Conference
EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES
03.01.2018 / 11:42
The issuer is solely responsible for the content of this announcement.
Hamburg, Germany, 03 January 2018:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at the 17th German Corporate Conference 2018 jointly hosted by UniCredit and Kepler Cheuvreux, Frankfurt, Germany, and will be attending the 36th Annual J.P. Morgan Healthcare Conference, San Francisco, USA, the Bankhaus Lampe German Equity Forum, London, UK, the BioCapital Europe 2018, Amsterdam, The Netherlands, and the 12th ODDO German Conference, Frankfurt, Germany.
36th Annual J.P. Morgan Healthcare Conference, San Francisco, USA
- Date: Monday, 08 January, until Thursday, 11 January 2018
- Venue: San Francisco, USA
17th German Corporate Conference 2018 jointly hosted by UniCredit and Kepler Cheuvreux, Frankfurt, Germany
- Date: Monday, 15 January 2018, 05.30 pm CET (04.30 pm GMT/11.30 am EST)
- Venue: Frankfurt, Germany
Bankhaus Lampe German Equity Forum, London, UK
- Date: Thursday, 01 February 2018
- Venue: London, UK
BioCapital Europe 2018, Amsterdam, The Netherlands
- Date: Tuesday, 06 February 2018
- Venue: Amsterdam, The Netherlands
12th ODDO German Conference, Frankfurt, Germany
- Date: Wednesday, 21 February 2018
- Venue: Frankfurt, Germany
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. For additional information please go to www.evotec.com and follow us on Twitter @EvotecAG.
FORWARD LOOKING STATEMENTS Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
03.01.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Manfred Eigen Campus / Essener Bogen 7
+49 (0)40 560 81-0
+49 (0)40 560 81-222
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
End of News
DGAP News Service
(Werbung)Ohne Depotgebühren. Mit Kosten-Airbag. Das Wertpapierdepot der MERKUR BANK.
LIVESTREAM: Mittwoch, 24. Januar ab 18 Uhr: Prof. Dr. Jack Mintz zu den Auswirkungen der US-amerikanischen Steuerreform
4investors Exklusiv-Berichte und Interviews:
Shop Apotheke Europe hat potenzielle Übernahmen in Deutschland im Blick
QSC will an der Börse und bei Kunden in die Offensive
STARAMBA SE: „Das Potenzial für STARAMBA.spaces ist riesig“